

1 **Paradoxical increases in anterior cingulate cortex activity**
2 **during nitrous oxide-induced analgesia reveal a signature of pain affect**

3
4 Jarret AP Weinrich^{1*}, Cindy D Liu^{1,2*}, Madison E Jewell¹, Christopher R Andolina¹, Mollie X
5 Bernstein¹, Jorge Benitez¹, Sian Rodriguez-Rosado¹, Joao M Braz¹, Mervyn Maze³, Mikhail I
6 Nemenov^{4,5}, & Allan I Basbaum^{1,2}

7 *These authors contributed equally to this work

8
9 ¹Department of Anatomy, ²Neuroscience Graduate Program, ³Department of Anesthesia and
10 Perioperative Care, University of California San Francisco, San Francisco, CA 94158, USA

11 ⁴Lasmed, Mountain View, CA 94043, USA

12 ⁵Department of Anesthesia, Stanford University School of Medicine, Stanford, CA 94035, USA

13

14 **Abstract**

15 The general consensus is that increases in neuronal activity in the anterior cingulate cortex (ACC)
16 contribute to pain's negative affect. Here, using *in vivo* imaging of neuronal calcium dynamics in
17 mice, we report that nitrous oxide, a general anesthetic that reduces pain affect, paradoxically,
18 increases ACC spontaneous activity. As expected, a noxious stimulus also increased ACC
19 activity. However, as nitrous oxide increases baseline activity, the relative change in activity from
20 pre-stimulus baseline was significantly less than the change in the absence of the general
21 anesthetic. We suggest that this relative change in activity represents a neural signature of the
22 affective pain experience. Furthermore, this signature of pain persists under general anesthesia
23 induced by isoflurane, at concentrations in which the mouse is unresponsive. We suggest that
24 this signature underlies the phenomenon of connected consciousness, in which use of the
25 isolated forelimb technique revealed that pain percepts can persist in anesthetized patients.

26

27 General anesthetics are potent regulators of pain processing and can produce effects ranging
28 from diminished or absent pain perception (i.e., analgesia¹⁻⁴) to the total abolition of reflexive
29 responses to ongoing surgical stimuli^{2,5}. Importantly, pain is a conscious, multidimensional
30 percept that includes both sensory-discriminative (modality, location, intensity) and affective-
31 motivational (unpleasantness) features⁶. Studies in awake, responsive patients inhaling nitrous
32 oxide, a general anesthetic gas with analgesic properties^{1,7,8}, report a preferential reduction of the
33 affective-motivational aspects of pain^{9,10}. Currently, however, there is limited information as to the
34 neural mechanisms that underlie the ability of nitrous oxide to modulate affective-motivational
35 aspects of pain.

36 The anterior cingulate cortex (ACC) is critical to processing the affective-motivational features of
37 the pain percept¹¹. In humans, primates, and rodents, ACC neurons respond to noxious, but not
38 innocuous, thermal and mechanical stimuli¹²⁻¹⁵. Human neuroimaging studies have shown that
39 increased ratings of the unpleasantness of pain correlate with increased ACC activity, and that
40 analgesia correlates with decreased ACC activity^{11,16}. Interestingly, after targeted ACC
41 manipulations, including ablations¹⁷⁻¹⁹ or deep brain stimulation^{20,21}, patients still sense noxious
42 stimuli, but report that the stimuli are less painful or less “bothersome”. Consistent with clinical
43 findings, ablative^{22,23} or pharmacological²⁴⁻²⁶ manipulations of the ACC in rodents produced
44 selective reduction in affective-motivational responses to pain without influencing sensory
45 thresholds²²⁻³². Importantly, these studies led to the conclusion that *inhibition*²²⁻²⁴ of the ACC is
46 critical to generating pain control and that *excitation*^{25,33-35} produces increased pain aversion.

47 Unexpectedly, and indeed paradoxically given the general consensus^{6,36}, cerebral blood flow and
48 metabolism-based measurements of neural activity report that nitrous oxide increases activity in
49 frontal cortical regions³⁷, and in particular in the ACC³⁸. However, because nitrous oxide has a
50 strong vasodilatory effect that confounds interpretations of data from neuroimaging studies^{39,40},
51 these findings are controversial. If true, these studies would suggest that increases in ACC activity
52 do not necessarily lead to increased pain aversion and may even contribute to the analgesic
53 effects of nitrous oxide. To date, however, there have been no direct measurements
54 (electrophysiology or *in vivo* calcium imaging) of neural activity in the ACC during inhalation of
55 nitrous oxide.

56 In this present work, using *in vivo* imaging of the calcium dynamics of ACC neurons in mice, we
57 report that nitrous oxide, in fact, produces profound increases in ACC activity. Furthermore, in
58 studies of molecularly distinct subsets of cortical neurons, we discovered that nitrous oxide
59 preferentially activates excitatory ACC neurons, with limited actions on inhibitory interneurons. In
60 behavioral studies, we confirmed that nitrous oxide produces a potent analgesia that preferentially
61 diminishes affective-motivational pain endpoints. In awake, freely moving mice, we demonstrated
62 that by increasing spontaneous ACC activity, nitrous oxide reduces the relative magnitude of
63 noxious stimulus-induced ACC activation. Importantly, this reduction in noxious stimulus-evoked
64 ACC activation correlates with nitrous oxide-induced reductions in affective-motivational
65 behaviors, but not reflexive behaviors. Lastly, using these changes in ACC as a neural biomarker
66 for affective-motivational aspects of pain, we demonstrate the presence of neural signatures of
67 pain even in an isoflurane-anesthetized, behaviorally unresponsive mouse.

68 **RESULTS**

69 ***Nitrous oxide induces paradoxical increases in ACC activity***

70 We used head-mounted miniature microscopes^{41,42} to monitor the calcium dynamics⁴³ of
71 individually identified ACC neurons during exposure to nitrous oxide or control gas (oxygen) (**Fig.**
72 **1A, B, Fig. S1**). Across the two separate exposures, we identified 1,364 neurons (nitrous oxide:

73 795, oxygen: 569). Consistently, we found that inhalation of nitrous oxide drove sustained and
74 significant increases in spontaneous ACC activity (**Fig. 1C**, **Supplemental Video 1**).

75 Next, we used clustering to identify distinct activity patterns that occur during inhalation of nitrous
76 oxide or control gas. Dimensionality reduction of neural activity patterns using t-distributed
77 stochastic neighbor embedding (tSNE) reveals that neural activity patterns during inhalation of
78 nitrous oxide are highly divergent and largely nonoverlapping with those observed during
79 inhalation of control gas (**Fig. 1D** and **E**). Density-based spatial clustering after tSNE analysis
80 identified 4 unique clusters of activity (**Fig. 1D** and **F**). Neurons identified during nitrous oxide
81 recordings predominately populated clusters defined by large increases in activity (**Fig. 1F**:
82 clusters 1, 2). Neurons from control gas recordings are largely confined to clusters with minimal
83 activity changes (**Fig. 1F**: cluster 3) or slightly decreased activity (**Fig. 1F**: cluster 4). Thus, in
84 sharp contrast to the established literature, we conclude that increased ACC activity can occur
85 during inhalation of a known analgesic.

86 ***Nitrous oxide preferentially activates excitatory ACC neurons in cortical layer 2/3***

87 Cortical circuits are comprised of functionally distinct neurons with unique molecular identities that
88 underlie cortical information processing⁴⁴⁻⁵¹. Using a combinatorial viral/genetic strategy that
89 enables the selective expression of genetically encoded calcium indicators within specific cell
90 types, we monitored the activity of principal (excitatory) neurons (vGluT2 expressing; VG2), and
91 molecularly distinct subpopulations of cortical inhibitory interneurons that express parvalbumin
92 (PV), somatostatin (SST), or vasoactive intestinal peptide (VIP) (**Fig. 2A, B**). During separate
93 exposures to nitrous oxide or control gas (oxygen) (**Fig. S1**), we identified 1,771 neurons (by
94 subtype: VG2: 846, PV: 296, SST: 260, VIP: 369; by gas: nitrous oxide: 1049, oxygen: 722).

95 **Figures 2C** and **S2** show that compared to oxygen, nitrous oxide preferentially activated
96 excitatory neurons. Although we do observe PV-, SST-, and VIP-expressing interneurons with
97 increased activity (**Fig. 2D**), the proportion of neurons with increased activity did not differ
98 between oxygen and nitrous oxide (**Fig. 2C** and **Fig. S2**). An assessment of the recruitment of
99 subtypes of neurons to clusters with distinct activity profiles confirmed that excitatory, but not
100 inhibitory (PV, SST, VIP), neurons are preferentially recruited to clusters with increased activity
101 (**Fig. 2E** and **F**: clusters 1 and 2).

102 Next, to provide a surrogate of overall neuronal activity in the ACC, we immunolabeled for Fos
103 protein (**Fig. 3A**), a molecular marker of recently activated neurons⁵². Paralleling our calcium
104 imaging observations (**Fig. 1**), we found that nitrous oxide increased Fos expression compared
105 to air (**Fig. 3B** and **C**). **Figure 3D** further shows that the increased Fos expression was particularly
106 pronounced in cortical layers 2/3 compared to other layers. Also consistent with the recordings,
107 we found a very small, albeit significant increase, from 3 to 6%, in Fos double-labeling of inhibitory
108 interneurons (GAD67-GFP+). This result indicates that the increased Fos expression observed in
109 layer 2/3 is largely due to activation of excitatory neurons. We conclude that nitrous oxide
110 preferentially activates excitatory neurons in the ACC, effects that we hypothesize profoundly alter
111 the experience of pain.

112 ***Nitrous oxide reduces affective-motivational pain-related behaviors***

113 Mice produce complex nocifensive behaviors to noxious stimuli. As noted above, alterations in
114 ACC activity are postulated to influence affective-motivational, but not reflexive, responses to
115 noxious stimuli. Here, we asked whether nitrous oxide-induced changes in ACC activity translate
116 to preferential reduction of affective-motivational, rather than reflexive, indices of pain. In these
117 studies, we compared the effects of nitrous oxide inhalation on the production of reflexive versus
118 affective-motivational behaviors during presentation of a noxious stimulus (**Fig. 4A** and **B**).

119 While mice inhaled nitrous oxide (60%) or control gas (air), we generated brief, noxious heat
120 stimuli using infrared laser pulses targeted to the hindpaw. The laser stimulus produced robust
121 nocifensive responses in mice, including withdrawals, shakes, and licks⁵³ (**Fig. 4B, Supplemental**
122 **Video 2**). Importantly, in rodents, licking of the hindpaw following a noxious stimulus is an
123 affective-motivational response indicative of the experience of pain^{27,54–56}, not merely a reflexive
124 response, as is the case for withdrawals and shakes^{55,57,58}. **Figure 4C** shows that nitrous oxide
125 produces a potent suppression of affective-motivational measures of pain. Indeed, nitrous oxide
126 almost completely abolished laser-evoked licks. In contrast, reflexive behaviors are minimally
127 affected by nitrous oxide (**Fig. 4C**).

128 In mice, a single laser stimulus often evokes multiple concurrent behaviors, with the production
129 of licks usually coupled to reflexive behaviors (i.e., withdrawals and shakes). Nitrous oxide
130 dramatically reduced this coupling, with laser-evoked reflexes producing proportionally fewer
131 concurrent licks (**Fig. 4D**). Taken together, we conclude that the reduction of affective-
132 motivational behaviors produced by nitrous oxide is independent of any effects on reflexive
133 behaviors.

134 ***Nitrous oxide-induced analgesia correlates with noxious stimulus-evoked ACC activity***

135 Next, we investigated how paradoxical, nitrous oxide-induced increases in spontaneous ACC
136 activity translate to an analgesic effect in response to a noxious stimulus. We hypothesized that
137 nitrous oxide-induced increases in ACC activity create a ceiling effect, thereby attenuating the
138 relative magnitude of noxious stimulus-evoked changes, which results in a diminished experience
139 of pain. To test this hypothesis, we imaged neural activity in ACC neurons during inhalation of
140 nitrous oxide (60%) or control gas (air) with concurrent delivery of the laser stimulus (**Fig. 4E,**
141 **Supplemental Video 3**). Given our finding that nitrous oxide predominantly increases activity in
142 excitatory neurons of the ACC, here we used a viral approach to monitor activity exclusively in
143 excitatory neurons (**Fig. 4E**). Across the nitrous oxide and air exposures, we identified 1402
144 neurons (nitrous oxide: 825, air: 577).

145 During presentation of the laser stimulus, we found that noxious stimulus responsive ACC
146 neurons accounted for $31.8 \pm 2.5\%$ of the total population in the air condition and $23.4 \pm 3.0\%$ under
147 nitrous oxide (**Fig. 4F, J**). In agreement with the findings described above, nitrous oxide
148 significantly increased the pre-stimulus baseline event rate compared to air (**Fig. 4G** and **I**).
149 Interestingly, and as would be expected for a ceiling effect, we observed no difference in the
150 absolute magnitude of laser-evoked activity between nitrous oxide and air conditions (**Fig. 4G**
151 and **I**). However, when measures of noxious stimulus-evoked activity were normalized to pre-
152 stimulus baseline activity there was a clear reduction in the nitrous oxide exposure as compared
153 to air (**Fig. 4H** and **I**). In other words, nitrous oxide reduces the relative magnitude of noxious
154 stimulus-evoked activity compared to air.

155 Importantly, the degree of laser-evoked licking behavior, but not reflexes, correlates not only with
156 the relative magnitude of the laser-evoked maximum event rate, but also with the percentage of
157 ACC neurons activated by the laser (**Fig. 4I, J**). These relationships suggest that noxious
158 stimulus-evoked neural activity of the ACC can indeed be used as a proxy for the affective-
159 motivational aspects of the pain experience in mice.

160 ***Neural signatures of pain are present during isoflurane-induced general anesthesia***

161 To date, aside from directly asking patients to rate levels of ongoing pain, there is no neural
162 biomarker that can be used as a proxy of the affective experience of pain. This lack of an adequate
163 pain biomarker is particularly problematic during general anesthesia, where patients (and
164 animals) are immobilized and thus behaviorally unresponsive and incapable of reporting their pain

165 experience⁵⁹. Rather disturbingly, clinical studies using the isolated forearm technique reveal that
166 patients often report the experience pain under general anesthesia^{60,61}. Fortunately, perhaps, the
167 amnestic effects of general anesthetics largely render them unable to recall such events
168 postoperatively⁶². As nitrous oxide does not produce loss of behavioral responsiveness in mice
169 under normal conditions (concentrations greater than 100% would be required), we could not
170 determine whether there is persistent brain activity in a nitrous oxide anesthetized mouse.
171 Therefore, we initiated studies using isoflurane, a widely used volatile anesthetic that readily
172 produces general anesthesia. Our specific question is whether there can be persistent ACC
173 activity consistent with the experience of pain in an otherwise anesthetized, behaviorally
174 unresponsive mouse.

175 We first assessed the influence of isoflurane on the spontaneous activity of ACC neurons. In
176 contrast to changes recorded during nitrous oxide inhalation, we found that isoflurane decreased
177 spontaneous ACC activity in a dose-dependent manner, and completely abolished ACC activity
178 at the highest concentrations (**Supplemental Video 4**).

179 We then assessed noxious stimulus-evoked ACC activity in isoflurane-anesthetized mice. As
180 expected, mice tested at 2% isoflurane, a concentration where nociceptive reflexes withdrawals
181 are abolished, we observed a complete absence of spontaneous and evoked activity.

182 Next, we tested mice during inhalation of 1% isoflurane in air, a concentration where mice are
183 immobilized and lack righting reflexes (a rodent measure of awareness), yet still retain neural
184 activity (**Fig. 5A and B**). Although laser stimulation increased the activity of ACC neurons in both
185 air and 1% isoflurane conditions (**Fig. 5C**), we recorded significantly fewer laser responsive
186 neurons under isoflurane (**Fig. 5G**). However, we found no significant differences between
187 baseline or laser-evoked ACC activity (i.e., event rate-based) measurements (**Fig. 5E, F, G**).

188 Lastly, using the relationship between noxious stimulus-evoked ACC activity and the generation
189 of affective-motivational behaviors (licks) recorded in nitrous oxide and air exposed mice
190 (**Supplemental Fig. 3**), we assessed the presence of neural activity patterns indicative of an
191 affective-motivational pain experience in isoflurane-anesthetized mice. Surprisingly, noxious
192 stimulus-evoked ACC activity during inhalation of 1% isoflurane, when mice could not perform
193 licks due to isoflurane-induced immobilization, not only persists, but is consistent with the
194 experience of pain (**Fig. 5H**). We conclude that a brain signature of affective-motivational aspects
195 of the pain experience can be preserved under general anesthesia.

196 **DISCUSSION**

197 In this study, we explored the influence of nitrous oxide, an inhalational anesthetic with analgesic
198 properties, on neural activity of the ACC, a cortical region that is a major contributor to the
199 affective-motivational aspects of pain⁶. In contrast to the prevailing view, namely that inhibition of
200 the ACC reduces pain affect²²⁻²⁴, we discovered that nitrous oxide profoundly increases
201 spontaneous ACC neuronal activity. Clearly, our results present a paradox: how is it that nitrous
202 oxide increases spontaneous ACC activity and produces analgesia, but does not, as the literature
203 would predict, increase affective-motivational indices of pain. Unexpectedly, we discovered that
204 the absolute magnitude ACC activity provoked by a noxious stimulus did not differ between nitrous
205 oxide and air, even though nitrous oxide reduced measures of the affective pain experience.
206 Rather, we demonstrate that it is the relative magnitude of noxious stimulus-evoked ACC activity,
207 as compared to activity immediately prior to the stimulus, that best correlates with the production
208 of affective-motivational pain behaviors. In essence, what underlies the affective-motivational
209 aspects of pain by the ACC is a circuit mechanism of gain control⁶³, namely one that adjusts the
210 signal-to-noise ratio of stimulus-evoked ACC neuronal activity⁶⁴. In this model, spontaneous
211 activity (i.e., noise) can be tuned, for example, by nitrous oxide, to modulate the relative change

212 of activity provoked by a noxious stimulus (i.e., signal). Based on our findings, we conclude that
213 increased activity *per se* is not necessarily indicative of a pain experience. Rather, it is the change
214 in between resting (spontaneous) ACC activity and that evoked by a noxious stimulus (e.g., laser
215 or surgical intervention) that determines whether there is pain affect. Of course, this conclusion is
216 consistent with the fact that despite ongoing activity in the naïve mouse (and human), there is no
217 pain affect until the introduction of a noxious stimulus.

218 Unclear is the mechanism underlying the selective increase in the activity of excitatory ACC
219 neurons by nitrous oxide, purportedly a non-competitive inhibitor of the NMDA receptor⁶⁵.
220 Although one would expect that blocking NMDA receptors would decrease neuronal activity,
221 previous recordings in the prefrontal cortex reported that selective NMDA receptor antagonists,
222 in fact, increase excitatory neuronal activity, not directly, but by decreasing the activity of inhibitory
223 interneurons⁶⁶. As we did not observe decreases in inhibitory interneuron activity, we suggest that
224 nitrous oxide's effects on the ACC involve alternative mechanisms⁶⁵. For example, nitrous oxide
225 could influence ACC neuronal activity via direct actions on upstream brain regions⁶⁷, such as
226 medial-dorsal thalamus or basolateral amygdala⁶⁸.

227 Also unclear are the direct downstream consequences of nitrous oxide-induced increases in ACC
228 activity, and how this translates to behavioral analgesia in tests of pain affect. The ACC is a major
229 hub that is highly connected to other elements of the so-called "pain matrix"⁶⁹. Thus, nitrous oxide-
230 induced activation of ACC projection neurons would produce wide-ranging effects on other
231 components of the matrix⁷⁰, thereby altering the experience of pain. Other studies reported that
232 nitrous oxide analgesia is naloxone reversible⁶⁵. In ongoing studies we are examining whether
233 the downstream circuits engaged by the ACC contribute to the naloxone-reversible aspects of
234 nitrous oxide-induced analgesia, potentially by direct actions on endorphin-mediated inhibitory
235 controls^{71,72}.

236 Particularly surprising was the persistence of noxious stimulus-evoked activity in the ACC of
237 isoflurane-anesthetized mice, at concentrations that blocked behavioral indices of pain affect,
238 namely, licking in response to a noxious stimulus. As this activity was comparable to that recorded
239 in awake mice, we suggest that it represents a neural biomarker, in effect a surrogate pain index
240 that is specific for the affective component of the pain experience. In other words, the brain can
241 "experience" pain even under general anesthesia, an interpretation consistent with provocative
242 clinical reports of the high prevalence of an intraoperative experience of pain in patients^{60-62,73}
243 under general anesthesia. These patients can communicate their pain experience in real time
244 through the isolated forearm technique⁵⁹⁻⁶¹, a phenomenon known as connected
245 consciousness⁵⁹.

246 Importantly, it is possible to establish a level of general anesthesia in which connected
247 consciousness does not occur⁷⁴. In fact, when we increased the depth of anesthesia using 2%
248 isoflurane and then tested the mice, not only was there no behavioral response to a noxious
249 stimulus, but we observed that both spontaneous and evoked ACC activity were abolished. This
250 absence of activity at the deepest levels of anesthesia⁷⁵ creates, in essence, a functional
251 "ablation" of the ACC, which blocks the experience of pain much in the same way that a physical
252 lesion of the ACC provides pain relief in patients¹⁷. However, although similarly deep levels of
253 general anesthesia (measured by EEG) can ensure the absence of connected consciousness⁷⁴,
254 the associated increased risk of adverse postoperative outcomes (death, stroke, postoperative
255 delirium)⁷⁶ likely outweigh any potential benefits. For this reason, our findings are particularly
256 relevant to ongoing efforts to develop neural activity-based biomarkers that can reliably document
257 adequate analgesia during surgery under general anesthesia⁷⁷, which, in turn, will support the
258 development of novel general anesthetics that can safely block the experience of pain.

259

260 **METHODS**

261 ***Animal husbandry***

262 All mouse husbandry and surgical procedures adhered to the regulatory standards of the
263 Institutional Animal Care and Use Committee of the University of California San Francisco (UCSF;
264 protocol AN199730). The following mouse strains were used: vGluT2-IRES-Cre⁷⁸ (Jax # 028863),
265 PV-IRES-Cre⁷⁹ (Jax #017320), SST-IRES-Cre⁸⁰ (Jax # 028864), VIP-IRES-Cre⁸⁰ (Jax # 031628),
266 Ai75D (ROSA26-nls-tdTomato; Jax # 025106), and GAD67-GFP⁸¹. The health and wellbeing of
267 the mice were monitored daily.

268 ***Calcium imaging of spontaneous ACC activity***

269 *GEC1 expression strategy*

270 We used two strategies to express genetically encoded calcium indicators (GEC1; GCaMP6f⁴³) in
271 neurons: (1) viral pan-neuronal expression, and (2) viral/genetic expression within molecular
272 distinct subsets of neurons. For experiments with pan-neuronal expression, we delivered
273 GCaMP6f under control of the synapsin promoter (AAV1/9-SYN-GCaMP6f; Addgene,
274 #100837)⁵¹. The restricted delivery of GCaMP6f to molecularly distinct populations of neurons
275 was achieved using the vGluT2-Cre⁷⁸, PV-Cre⁷⁹, SST-Cre⁸⁰, or VIP-Cre⁸⁰ mouse lines in
276 combination with the Cre-inducible viral expression of GCaMP6f in the ACC (AAV1/9-SYN-FLEX-
277 GCaMP6f; Addgene, #100833).

278 *Surgical preparation for ACC calcium imaging*

279 Briefly, mice were anesthetized with isoflurane (2% in oxygen) and placed on a stereotaxic frame
280 (Kopf). After craniotomy above the left ACC (Bregma, x: -0.33mm, y:1.27mm), we injected virus
281 (depth: -1.75mm), and chronically implanted a gradient index (GRIN) lens (0.5x4mm ProView,
282 Inscopix; depth: -1.7mm). The GRIN lens and titanium headbar (custom made,
283 eMachineShop.com) were affixed to the skull with dental cement (Metabond). Mice were provided
284 with postoperative analgesia (carprofen and slow-release buprenorphine). One week after
285 implantation surgery, under isoflurane anesthesia, a baseplate was affixed above the GRIN lens
286 with dental cement. To provide time for sufficient GCaMP6f expression, mice recovered for 3 to
287 4 weeks before experiments began.

288 *Behavioral apparatus and anesthesia delivery*

289 Mice were headfixed to a passive treadmill⁸², which was modified to provide heating that kept the
290 mice isothermic during exposure to anesthesia, and then placed in a modified anesthetic induction
291 chamber (VetEquip, 7L). Before the start of the experiment, the atmosphere of the chamber was
292 replaced with oxygen. During experimental sessions, the mice were exposed to continually
293 increasing concentrations of isoflurane or nitrous oxide, or for control conditions, continued
294 exposure to oxygen. For all experiments, the concentration of oxygen never fell below 21%.
295 Isoflurane was delivered via an Isoflurane Vaporizer (DRE Veterinary). Gas concentrations were
296 monitored by a Datex Ohmeda S/5 anesthesia patient monitor and recorded by VSCapture
297 software.

298 *Calcium imaging and behavior monitoring*

299 Changes in GCaMP6f fluorescence were captured with Inscopix miniscopes (nVista 3.0 or nVoke
300 2.0) at 20 frames per second (fps). Imaging parameters (excitation LED power, digital gain, and
301 focus depth) were individually set for each mouse. Calcium imaging data were recorded via
302 Inscopix Data Acquisition Software (IDAS), and recordings were triggered via TTL input. The
303 behavior of the mouse was monitored with a Logitech webcam and recorded via ffmpeg software

304 (<https://ffmpeg.org/>). Recording sessions were coordinated by Arduino/MATLAB, which triggered
305 the start and end of data acquisition via miniscopes, ffmpeg, and VSCapture.

306 *Tissue processing*

307 After completion of the *in vivo* imaging experiments, the mice were anesthetized with Avertin
308 (2.5% in saline) and transcardially perfused with phosphate-buffered saline (PBS) and then 4%
309 formaldehyde (37% formaldehyde; Acros Organics, 11969-0100) diluted in PBS. Whole heads
310 were postfixed in 4% formaldehyde at 4°C overnight, then brains were extracted from the skull
311 and postfixed overnight at 4°C. Following postfixation, the brains were cryoprotected at 4°C
312 overnight in 30% sucrose in PBS, and embedded in specimen matrix (Optimal Cutting
313 Temperature (OCT) compound, Tissue-Tek) and stored at -80°C. Confocal microscopy confirmed
314 GCaMP6f expression and proper GRIN lens targeting.

315 **Assessing induction of immediate early genes by nitrous oxide**

316 *Fos induction*

317 Adult GAD67-GFP mice (6-10 weeks old) were habituated to an anesthetic induction chamber
318 (7L, VetEquip) for 30-minute sessions on 3 separate days. The following day, after an additional
319 30 minute habituation, the mice were exposed to 2L/minute of 60% nitrous oxide or medical air.
320 After 2 hours, the mice were anesthetized with Avertin and transcardially perfused as described
321 above. The brain was then removed, post-fixed in 4% formaldehyde for 4 hours at 4°C and then
322 cryoprotected in 30% sucrose, embedded in OCT, frozen on dry ice, and stored at -80°C.

323 *Fos immunohistochemistry and confocal imaging*

324 Frozen brains were coronally sectioned (30 microns) with a Hacker cryostat (Bright OTF series).
325 ACC sections were slide mounted, washed with PBS (3 times for 5 minutes), and blocked with
326 10% normal goat serum (NGS) in PBS for 1 hour. Slides were incubated overnight at room
327 temperature in rabbit anti-Fos primary antibody (1:1000, Cell Signaling Technology) diluted in
328 PBS with 0.3% Triton-X and 1% NGS (PBST). Slides were then washed with PBS (3 times for 5
329 minutes), incubated in AlexaFluor 594-conjugated goat anti-rabbit secondary antibody (1:1000,
330 Invitrogen) diluted in PBST at room temperature for one hour, and washed again with PBS (3
331 times for 5 minutes). Sections were coated with mounting media (DAPI Fluoromount-G, Southern
332 Biotech, #0100-20), and then coverslipped with #1.5 glass (Eprexia, #152460). Fos
333 immunofluorescence was captured via epifluorescent microscopy using a Zeiss Axio Zoom.V16.
334 Colocalization of GAD67-GFP and Fos was captured by confocal microscopy using a Zeiss
335 LSM980 Airyscan II microscope.

336 *Fos image analysis and quantification*

337 Fos expression was quantified using a thresholded z-scoring approach with custom-written
338 MATLAB code. Briefly, we used the intensity values of pixels in cortical layer 1, which has minimal
339 Fos expression, to set the mean and standard deviation for image z-scoring. The intensity of all
340 pixels within an image were z-scored as: $(\text{Pixel intensity} - \text{mean background intensity}) / (\text{standard}$
341 $\text{deviation of background intensity})$. Pixels within the ACC that have z-score values above 1.96
342 were considered Fos+. Double labeling of GAD67-GFP and Fos immunolabeling was quantified
343 within ImageJ by a blind scorer.

344 **Assessing noxious stimulus-evoked responses to infrared laser pulses**

345 *Behavioral apparatus and volatile anesthetic delivery*

346 Mice were placed inside a modified anesthetic induction chamber (VetEquip, 2L) with a high-
347 transmittance glass floor that allowed for the presentation of noxious heat stimuli during the
348 concurrent inhalation of nitrous oxide. During experimental sessions, mice were exposed to
349 nitrous oxide (60%) or control gas (medical air). We used subhypnotic concentrations of nitrous
350 oxide that allowed awake, weightbearing mice to freely respond to noxious stimuli⁸³, but below
351 concentrations that induce unconsciousness (i.e., MAC_{awake})^{84,85}. The concentration of oxygen
352 was held equivalent to atmospheric concentrations (21%) during nitrous oxide inhalation.
353 Concentrations of nitrous oxide, oxygen, and carbon dioxide were monitored by a Datex Ohmeda
354 S/5 anesthesia patient monitor and recorded using VSCapture software⁸⁶. Individual mice were
355 tested with different gasses during separate experimental sessions using a crossover study
356 design with a minimum washout period of 7 days.

357 *Generation of acute noxious thermal stimuli*

358 Acute noxious thermal stimuli were generated using a fiber-attached infrared diode laser
359 (LASMED (Lass-7M) 7W 975nm laser) that produced brief pulses that rapidly heat skin without
360 causing injury^{53,87}. Mice received 10 trials of laser stimuli, with one laser pulse per trial. The laser
361 power and pulse duration were set to 1750mA and 300 milliseconds, respectively. During
362 presentation of the laser stimulus, a focused beam (2.0mm, $1/e^2$ diameter) was shone on the
363 central portion of the plantar surface of the hindpaw⁵³. The laser stimulus was manually triggered
364 via a footswitch and laser firing time was recorded via Arduino/MATLAB. Behavioral responses
365 were recorded with a digital camera (Imaging Source, DMK 37BUX252) at 200 frames per second
366 (fps) using StreamPix (Norpix) software.

367 **Calcium imaging of noxious stimulus-evoked ACC activity**

368 *ACC calcium imaging preparation*

369 Mice were prepared for calcium imaging as described above, with the following differences: (1)
370 GCaMP6f was virally expressed in excitatory neurons using the CaMKIIa promotor (AAV1/9-
371 CaMKIIa-GCaMP6f, Inscopix), (2) viral injection and implantation of an integrated GRIN
372 lens/baseplate (0.5x4mm, Inscopix) occurred within a single surgery.

373 *Calcium imaging and behavior monitoring*

374 Changes in GCaMP6f fluorescence were monitored and noxious heat stimuli were generated as
375 described above. For nitrous oxide recordings, anesthesia and behavioral monitoring were
376 performed as for the laser experiments. For recordings under isoflurane anesthesia, mice were
377 first tested during inhalation of air as described above. Then, mice were briefly anesthetized with
378 1.0% isoflurane within the recording chamber, and then moved from the chamber to a heating
379 pad where isoflurane was administered via nosecone. Mice were equilibrated to isoflurane
380 anesthesia for 30 minutes to ensure steady-state concentrations within the brain⁸⁸ before testing
381 resumed. This equilibration process was repeated for recordings conducted under 2% isoflurane.
382 Miniscope recording, laser pulses and behavioral camera recording signals were coordinated via
383 TTL pulse via Arduino/MATLAB and synchronized by monitoring TTL signals via Inscopix DAQ
384 (data acquisition) box.

385 **Data processing**

386 *Calcium imaging data processing*

387 Calcium imaging data were processed with Inscopix Data Processing Software (IDPS), MATLAB-
388 IDPS API, and custom MATLAB code. Briefly, raw videos are spatially cropped, downsampled
389 (2X), and bandpass filtered⁸⁹. Processed videos are then motion corrected, normalized (dF/F),

390 and individual cells segmented using principal component analysis and independent component
391 analysis (PCA/ICA)⁹⁰. Cell segmentation is manually confirmed in the IDPS GUI for each identified
392 cell. Changes in calcium fluorescence per cell are extracted, and individual calcium transients
393 within a trace are extracted as events, using either event detection algorithm in IDPS or custom
394 MATLAB code.

395 *Calcium imaging data analysis*

396 To demonstrate nitrous oxide-induced increases in spontaneous activity, we Z-score normalized
397 the activity of each cell to the baseline event rate. For clustering analysis, z-scored neuronal
398 activity was transformed by dimensional reduction using tSNE algorithm. Clusters of neurons with
399 unique activity patterns were identified from the tSNE mapping using DBSCAN. For stimulus-
400 evoked changes, activity was extracted from 10 separate presentations of the noxious laser
401 stimulus. The timing of stimulus presentation was determined using laser-generated TTL pulses
402 recorded via the Inscopix nVoke DAQ box. Pre-stimulus activity is the time from -5 to 0 seconds
403 before the laser stimulus; post-stimulus activity is measured from 0 seconds to 5 seconds after
404 the laser stimulus. Baseline event rate is the mean pre-stimulus event rate per neuron per mouse.
405 The maximum event rate is the maximum post-stimulus event rate. Where noted, fold changes in
406 measures of neural activity are calculated as post-stimulus activity divided by pre-stimulus activity.
407 Fluorescence traces were used to calculate the percentage of neurons with stimulus-evoked
408 activity. Traces were z-scored to pre-stimulus activity and considered to have evoked activity if
409 the trace z-scored value was greater than 1.96 for the post-stimulus period. Stepwise linear
410 regression with interaction effects was performed on data mean-centered to control gas condition
411 (medical air only). A neural activity (biomarker)-based estimate of laser evoked licks that
412 otherwise would occur in awake mice was predicted from ACC recordings in isoflurane
413 anesthetized mice. The isoflurane data were mean-centered to the control gas (medical air), and
414 a prediction was made using the linear regression model generated from nitrous oxide and air
415 recordings.

416 *Scoring of stimulus-evoked behaviors*

417 We used custom MATLAB software to score behavioral videos (viewed at 1/5X speed).
418 Behavioral responses to individual laser stimuli were categorized as: (a) no response, (b) reflexes,
419 such as flinches (the stimulated hindpaw shifted position but did not leave the glass floor),
420 withdrawals (the stimulated hindpaw is rapidly pulled off of the glass floor), or shakes (the
421 stimulated hindpaw is moved in a repetitive oscillatory fashion), or (c) licks (the stimulated
422 hindpaw is brought to the face and licked or bitten). Each video was scored independently by two
423 individuals. All scorers were blind to experimental conditions.

424 **Statistical analyses**

425 Data were processed and analyzed in Mathwork's MATLAB (R2020a) software. Statistical tests
426 were performed with Prism (GraphPad) software. The threshold for significance for all statistical
427 tests was set at $p < 0.05$, and indicators of significance levels were as follows: ns (not significant;
428 $p > 0.05$); * = $p < 0.05$; ** = $p < 0.01$; *** = $p < 0.001$; and **** = $p < 0.0001$. Corrections for multiple
429 comparisons were performed using the false discovery rate method of Benjamini, Krieger, and
430 Yekutieli, and noted within figure legends as "FDR corrected".

431

432 **ACKNOWLEDGEMENTS**

433 This work was funded by NIH NSR35NS097306 (AIB), Open Philanthropy (AIB), NIGMS
434 fellowship F32GM131479 (JAPW), and Canadian Institutes of Health Research (CIHR) Doctoral

435 Foreign Study Award DFD-170771 (CDL). We are grateful to: Dr. Eric Lam (UCSF) for aiding in
436 the design and fabrication of experimental setups; Dr. Philip Bickler (UCSF) for advice on
437 experimental setup; Dr. Racheli Werberger (UCSF) for helpful advice on calcium imaging and
438 analyses; Dr. Chris Tsang (Inscopix) for initial training for surgical implant of GRIN lenses; Dr.
439 Julian Motzkin (UCSF) for helpful discussions on data analysis and statistics.

440

441 **SUPPLEMENTAL VIDEOS**

442 **Supplemental Video 1. Nitrous oxide-induced changes in pan-neuronal ACC activity.** *In vivo*
443 calcium imaging of ACC activity during inhalation of increasing concentrations of nitrous oxide.
444 GCaMP6f fluorescence is normalized (dF/F). Video is played at 10X speed.

445 **Supplemental Video 2. Behavioral responses to laser stimuli.** Representative videos of lack
446 of response, or laser-evoked responses (withdrawal, shake, lick).

447 **Supplemental Video 3. Laser-evoked ACC activity with simultaneous behavior monitoring.**
448 Left: Front view of mouse in anesthesia chamber during miniscope recording with concurrent laser
449 stimulation. Middle: Bottom view of mouse during laser stimulus. Right: Laser-evoked activity in
450 the ACC (dF/F normalized).

451 **Supplemental Video 4. Isoflurane-induced changes in pan-neuronal ACC activity.** *In vivo*
452 calcium imaging of ACC activity during inhalation of increasing concentrations of isoflurane.
453 GCaMP6f fluorescence is normalized (dF/F). Video is played at 10X speed.

454

455 **REFERENCES**

456 1. Davy, H. *Researches, Chemical and Philosophical; Chiefly Concerning Nitrous Oxide: Or*
457 *Dephlogisticated Nitrous Air, and Its Respiration*. 588 (1800).

458 2. Snow, J. D. On the inhalation of the vapour of ether in surgical operations: Part I. in *On*
459 *the inhalation of the vapour of ether in surgical operations* (John Churchill, 1847).

460 3. Coffey, F. *et al.* STOP!: a randomised, double-blind, placebo-controlled study of the
461 efficacy and safety of methoxyflurane for the treatment of acute pain. *Emerg. Med. J.* **31**,
462 613–618 (2014).

463 4. Olofsen, E. *et al.* Ketamine psychedelic and antinociceptive effects are connected.
464 *Anesthesiology* **136**, 792–801 (2022).

465 5. Merkel, G. & Eger, E. I. A comparative study of halothane and halopropane anesthesia
466 including method for determining equipotency. *Anesthesiology* **24**, 346–357 (1963).

- 467 6. Basbaum, A. I., Bautista, D. M., Scherrer, G. & Julius, D. Cellular and molecular
468 mechanisms of pain. *Cell* **139**, 267–284 (2009).
- 469 7. Sanders, R. D., Weimann, J. & Maze, M. Biologic effects of nitrous oxide: a mechanistic
470 and toxicologic review. *Anesthesiology* **109**, 707–722 (2008).
- 471 8. Lew, V., McKay, E. & Maze, M. Past, present, and future of nitrous oxide. *Br. Med. Bull.*
472 **125**, 103–119 (2018).
- 473 9. Pirec, V., Patterson, T. H., Thapar, P., Apfelbaum, J. L. & Zacny, J. P. Effects of
474 subanesthetic concentrations of nitrous oxide on cold-pressor pain in humans.
475 *Pharmacol. Biochem. Behav.* **51**, 323–329 (1995).
- 476 10. Ramsay, D. S., Brown, A. C. & Woods, S. C. Acute tolerance to nitrous oxide in humans.
477 *Pain* **51**, 367–373 (1992).
- 478 11. Rainville, P., Duncan, G. H., Price, D. D., Carrier, B. & Bushnell, M. C. Pain affect
479 encoded in human anterior cingulate but not somatosensory cortex. *Science* **277**, 968–
480 971 (1997).
- 481 12. Hutchison, W. D., Davis, K. D., Lozano, A. M., Tasker, R. R. & Dostrovsky, J. O. Pain-
482 related neurons in the human cingulate cortex. *Nat. Neurosci.* **2**, 403–405 (1999).
- 483 13. Kuo, C.-C. & Yen, C.-T. Comparison of anterior cingulate and primary somatosensory
484 neuronal responses to noxious laser-heat stimuli in conscious, behaving rats. *J.*
485 *Neurophysiol.* **94**, 1825–1836 (2005).
- 486 14. Iwata, K. *et al.* Anterior cingulate cortical neuronal activity during perception of noxious
487 thermal stimuli in monkeys. *J. Neurophysiol.* **94**, 1980–1991 (2005).

- 488 15. Kuo, C.-C., Chiou, R.-J., Liang, K.-C. & Yen, C.-T. Differential involvement of the anterior
489 cingulate and primary sensorimotor cortices in sensory and affective functions of pain. *J.*
490 *Neurophysiol.* **101**, 1201–1210 (2009).
- 491 16. Kröger, I. L. & May, A. Central effects of acetylsalicylic acid on trigeminal-nociceptive
492 stimuli. *J. Headache Pain* **15**, 59 (2014).
- 493 17. Foltz, E. L. & White, L. E. Pain “relief” by frontal cingulumotomy. *J. Neurosurg.* **19**, 89–
494 100 (1962).
- 495 18. Agarwal, N., Choi, P. A., Shin, S. S., Hansberry, D. R. & Mammis, A. Anterior
496 cingulotomy for intractable pain. *Interdisciplinary Neurosurgery* **6**, 80–83 (2016).
- 497 19. Strauss, I. *et al.* Double anterior stereotactic cingulotomy for intractable oncological pain.
498 *Stereotact. Funct. Neurosurg.* **95**, 400–408 (2017).
- 499 20. Spooner, J., Yu, H., Kao, C., Sillay, K. & Konrad, P. Neuromodulation of the cingulum for
500 neuropathic pain after spinal cord injury. Case report. *J. Neurosurg.* **107**, 169–172 (2007).
- 501 21. Farrell, S. M., Green, A. & Aziz, T. The current state of deep brain stimulation for chronic
502 pain and its context in other forms of neuromodulation. *Brain Sci.* **8**, (2018).
- 503 22. Johansen, J. P., Fields, H. L. & Manning, B. H. The affective component of pain in
504 rodents: direct evidence for a contribution of the anterior cingulate cortex. *Proc Natl Acad*
505 *Sci USA* **98**, 8077–8082 (2001).
- 506 23. Juarez-Salinas, D. L. *et al.* GABAergic cell transplants in the anterior cingulate cortex
507 reduce neuropathic pain aversiveness. *Brain* **142**, 2655–2669 (2019).

- 508 24. LaGraize, S. C. & Fuchs, P. N. GABAA but not GABAB receptors in the rostral anterior
509 cingulate cortex selectively modulate pain-induced escape/avoidance behavior. *Exp.*
510 *Neurol.* **204**, 182–194 (2007).
- 511 25. Johansen, J. P. & Fields, H. L. Glutamatergic activation of anterior cingulate cortex
512 produces an aversive teaching signal. *Nat. Neurosci.* **7**, 398–403 (2004).
- 513 26. Bannister, K. *et al.* Multiple sites and actions of gabapentin-induced relief of ongoing
514 experimental neuropathic pain. *Pain* **158**, 2386–2395 (2017).
- 515 27. Donahue, R. R., LaGraize, S. C. & Fuchs, P. N. Electrolytic lesion of the anterior
516 cingulate cortex decreases inflammatory, but not neuropathic nociceptive behavior in
517 rats. *Brain Res.* **897**, 131–138 (2001).
- 518 28. LaGraize, S. C., Borzan, J., Peng, Y. B. & Fuchs, P. N. Selective regulation of pain affect
519 following activation of the opioid anterior cingulate cortex system. *Exp. Neurol.* **197**, 22–
520 30 (2006).
- 521 29. Qu, C. *et al.* Lesion of the rostral anterior cingulate cortex eliminates the aversiveness of
522 spontaneous neuropathic pain following partial or complete axotomy. *Pain* **152**, 1641–
523 1648 (2011).
- 524 30. Navratilova, E. *et al.* Endogenous opioid activity in the anterior cingulate cortex is
525 required for relief of pain. *J. Neurosci.* **35**, 7264–7271 (2015).
- 526 31. Gomtsian, L. *et al.* Morphine effects within the rodent anterior cingulate cortex and
527 rostral ventromedial medulla reveal separable modulation of affective and sensory
528 qualities of acute or chronic pain. *Pain* **159**, 2512–2521 (2018).
- 529 32. Barthas, F. *et al.* The anterior cingulate cortex is a critical hub for pain-induced
530 depression. *Biol. Psychiatry* **77**, 236–245 (2015).

- 531 33. Fuchs, P. N., Peng, Y. B., Boyette-Davis, J. A. & Uhelski, M. L. The anterior cingulate
532 cortex and pain processing. *Front. Integr. Neurosci.* **8**, 35 (2014).
- 533 34. Terrasa, J. L. *et al.* Anterior cingulate cortex activity during rest is related to alterations in
534 pain perception in aging. *Front. Aging Neurosci.* **13**, 695200 (2021).
- 535 35. Kasanetz, F. & Nevian, T. Increased burst coding in deep layers of the ventral anterior
536 cingulate cortex during neuropathic pain. *Sci. Rep.* **11**, 24240 (2021).
- 537 36. Devinsky, O., Morrell, M. J. & Vogt, B. A. Contributions of anterior cingulate cortex to
538 behaviour. *Brain* **118 (Pt 1)**, 279–306 (1995).
- 539 37. Deutsch, G. & Samra, S. K. Effects of nitrous oxide on global and regional cortical blood
540 flow. *Stroke* **21**, 1293–1298 (1990).
- 541 38. Gyulai, F. E., Firestone, L. L., Mintun, M. A. & Winter, P. M. In vivo imaging of human
542 limbic responses to nitrous oxide inhalation. *Anesth. Analg.* **83**, 291–298 (1996).
- 543 39. Dashdorj, N. *et al.* Effects of subanesthetic dose of nitrous oxide on cerebral blood flow
544 and metabolism: a multimodal magnetic resonance imaging study in healthy volunteers.
545 *Anesthesiology* **118**, 577–586 (2013).
- 546 40. Reinstrup, P. *et al.* Regional cerebral metabolic rate (positron emission tomography)
547 during inhalation of nitrous oxide 50% in humans. *Br. J. Anaesth.* **100**, 66–71 (2008).
- 548 41. Ghosh, K. K. *et al.* Miniaturized integration of a fluorescence microscope. *Nat. Methods*
549 **8**, 871–878 (2011).
- 550 42. Corder, G. *et al.* An amygdalar neural ensemble that encodes the unpleasantness of
551 pain. *Science* **363**, 276–281 (2019).

- 552 43. Chen, T.-W. *et al.* Ultrasensitive fluorescent proteins for imaging neuronal activity.
553 *Nature* **499**, 295–300 (2013).
- 554 44. Zeisel, A. *et al.* Brain structure. Cell types in the mouse cortex and hippocampus
555 revealed by single-cell RNA-seq. *Science* **347**, 1138–1142 (2015).
- 556 45. Tasic, B. *et al.* Adult mouse cortical cell taxonomy revealed by single cell
557 transcriptomics. *Nat. Neurosci.* **19**, 335–346 (2016).
- 558 46. Fuzik, J. *et al.* Integration of electrophysiological recordings with single-cell RNA-seq
559 data identifies neuronal subtypes. *Nat. Biotechnol.* **34**, 175–183 (2016).
- 560 47. Harris, K. D. & Mrsic-Flogel, T. D. Cortical connectivity and sensory coding. *Nature* **503**,
561 51–58 (2013).
- 562 48. Niell, C. M. & Scanziani, M. How cortical circuits implement cortical computations:
563 mouse visual cortex as a model. *Annu. Rev. Neurosci.* **44**, 517–546 (2021).
- 564 49. Blackwell, J. M. & Geffen, M. N. Progress and challenges for understanding the function
565 of cortical microcircuits in auditory processing. *Nat. Commun.* **8**, 2165 (2017).
- 566 50. Wood, K. C., Blackwell, J. M. & Geffen, M. N. Cortical inhibitory interneurons control
567 sensory processing. *Curr. Opin. Neurobiol.* **46**, 200–207 (2017).
- 568 51. Cichon, J., Blanck, T. J. J., Gan, W.-B. & Yang, G. Activation of cortical somatostatin
569 interneurons prevents the development of neuropathic pain. *Nat. Neurosci.* **20**, 1122–
570 1132 (2017).
- 571 52. Dragunow, M. & Faull, R. The use of c-fos as a metabolic marker in neuronal pathway
572 tracing. *J. Neurosci. Methods* **29**, 261–265 (1989).


- 573 53. Mitchell, K. *et al.* Nociception and inflammatory hyperalgesia evaluated in rodents using
574 infrared laser stimulation after Trpv1 gene knockout or resiniferatoxin lesion. *Pain* **155**,
575 733–745 (2014).
- 576 54. Roome, R. B. *et al.* Phox2a defines a developmental origin of the anterolateral system in
577 mice and humans. *Cell Rep.* **33**, 108425 (2020).
- 578 55. Wheeler-Aceto, H. & Cowan, A. Standardization of the rat paw formalin test for the
579 evaluation of analgesics. *Psychopharmacology (Berl)* **104**, 35–44 (1991).
- 580 56. Huang, T. *et al.* Identifying the pathways required for coping behaviours associated with
581 sustained pain. *Nature* **565**, 86–90 (2019).
- 582 57. Sherrington, C. S. *The integrative action of the nervous system.* (Yale University Press,
583 1911). doi:10.1037/13798-000.
- 584 58. Bradley, N. S. & Smith, J. L. Neuromuscular patterns of stereotypic hindlimb behaviors in
585 the first two postnatal months. III. Scratching and the paw-shake response in kittens.
586 *Brain Res.* **466**, 69–82 (1988).
- 587 59. Sanders, R. D., Tononi, G., Laureys, S. & Sleigh, J. W. Unresponsiveness ≠
588 unconsciousness. *Anesthesiology* **116**, 946–959 (2012).
- 589 60. Sanders, R. D. *et al.* Incidence of Connected Consciousness after Tracheal Intubation: A
590 Prospective, International, Multicenter Cohort Study of the Isolated Forearm Technique.
591 *Anesthesiology* **126**, 214–222 (2017).
- 592 61. Lennertz, R. *et al.* Connected consciousness after tracheal intubation in young adults: an
593 international multicentre cohort study. *Br. J. Anaesth.* (2022)
594 doi:10.1016/j.bja.2022.04.010.

- 595 62. Sebel, P. S. *et al.* The incidence of awareness during anesthesia: a multicenter United
596 States study. *Anesth. Analg.* **99**, 833–839 (2004).
- 597 63. Quikempoix, M. *et al.* Layer 2/3 pyramidal neurons control the gain of cortical output.
598 *Cell Rep.* **24**, 2799-2807.e4 (2018).
- 599 64. Vander Weele, C. M. *et al.* Dopamine enhances signal-to-noise ratio in cortical-
600 brainstem encoding of aversive stimuli. *Nature* **563**, 397–401 (2018).
- 601 65. Fujinaga, M. & Maze, M. Neurobiology of nitrous oxide-induced antinociceptive effects.
602 *Mol. Neurobiol.* **25**, 167–189 (2002).
- 603 66. Homayoun, H. & Moghaddam, B. NMDA receptor hypofunction produces opposite
604 effects on prefrontal cortex interneurons and pyramidal neurons. *J. Neurosci.* **27**, 11496–
605 11500 (2007).
- 606 67. Fillinger, C., Yalcin, I., Barrot, M. & Veinante, P. Afferents to anterior cingulate areas 24a
607 and 24b and midcingulate areas 24a' and 24b' in the mouse. *Brain Struct. Funct.* **222**,
608 1509–1532 (2017).
- 609 68. Meda, K. S. *et al.* Microcircuit Mechanisms through which Mediodorsal Thalamic Input to
610 Anterior Cingulate Cortex Exacerbates Pain-Related Aversion. *Neuron* **102**, 944-959.e3
611 (2019).
- 612 69. Tracey, I. & Johns, E. The pain matrix: reloaded or reborn as we image tonic pain using
613 arterial spin labelling. *Pain* **148**, 359–360 (2010).
- 614 70. Peeters, L. M. *et al.* Chemogenetic silencing of neurons in the mouse anterior cingulate
615 area modulates neuronal activity and functional connectivity. *Neuroimage* **220**, 117088
616 (2020).

- 617 71. Basbaum, A. I. & Fields, H. L. Endogenous pain control systems: brainstem spinal
618 pathways and endorphin circuitry. *Annu. Rev. Neurosci.* **7**, 309–338 (1984).
- 619 72. Fillinger, C., Yalcin, I., Barrot, M. & Veinante, P. Efferents of anterior cingulate areas 24a
620 and 24b and midcingulate areas 24a' and 24b' in the mouse. *Brain Struct. Funct.* **223**,
621 1747–1778 (2018).
- 622 73. Linassi, F., Zanatta, P., Tellaroli, P., Ori, C. & Carron, M. Isolated forearm technique: a
623 meta-analysis of connected consciousness during different general anaesthesia
624 regimens. *Br. J. Anaesth.* **121**, 198–209 (2018).
- 625 74. Gaskell, A. L. *et al.* Frontal alpha-delta EEG does not preclude volitional response during
626 anaesthesia: prospective cohort study of the isolated forearm technique. *Br. J. Anaesth.*
627 **119**, 664–673 (2017).
- 628 75. Ní Mhuircheartaigh, R., Warnaby, C., Rogers, R., Jbabdi, S. & Tracey, I. Slow-wave
629 activity saturation and thalamocortical isolation during propofol anesthesia in humans.
630 *Sci. Transl. Med.* **5**, 208ra148 (2013).
- 631 76. Pawar, N. & Barreto Chang, O. L. Burst suppression during general anesthesia and
632 postoperative outcomes: mini review. *Front. Syst. Neurosci.* **15**, 767489 (2021).
- 633 77. García, P. S., Kreuzer, M., Hight, D. & Sleigh, J. W. Effects of noxious stimulation on the
634 electroencephalogram during general anaesthesia: a narrative review and approach to
635 analgesic titration. *Br. J. Anaesth.* **126**, 445–457 (2021).
- 636 78. Vong, L. *et al.* Leptin action on GABAergic neurons prevents obesity and reduces
637 inhibitory tone to POMC neurons. *Neuron* **71**, 142–154 (2011).
- 638 79. Hippenmeyer, S. *et al.* A developmental switch in the response of DRG neurons to ETS
639 transcription factor signaling. *PLoS Biol.* **3**, e159 (2005).

- 640 80. Taniguchi, H. *et al.* A resource of Cre driver lines for genetic targeting of GABAergic
641 neurons in cerebral cortex. *Neuron* **71**, 995–1013 (2011).
- 642 81. Tamamaki, N. *et al.* Green fluorescent protein expression and colocalization with
643 calretinin, parvalbumin, and somatostatin in the GAD67-GFP knock-in mouse. *J. Comp.*
644 *Neurol.* **467**, 60–79 (2003).
- 645 82. Jackson, J., Karnani, M. M., Zemelman, B. V., Burdakov, D. & Lee, A. K. Inhibitory
646 control of prefrontal cortex by the claustrum. *Neuron* **99**, 1029-1039.e4 (2018).
- 647 83. Alkire, M. T. & Gorski, L. A. Relative amnesic potency of five inhalational anesthetics
648 follows the Meyer-Overton rule. *Anesthesiology* **101**, 417–429 (2004).
- 649 84. Dwyer, R., Bennett, H. L., Eger, E. I. & Heilbron, D. Effects of isoflurane and nitrous
650 oxide in subanesthetic concentrations on memory and responsiveness in volunteers.
651 *Anesthesiology* **77**, 888–898 (1992).
- 652 85. Eger, E. I. Age, minimum alveolar anesthetic concentration, and minimum alveolar
653 anesthetic concentration-awake. *Anesth. Analg.* **93**, 947–953 (2001).
- 654 86. Karippacheril, J. G. & Ho, T. Y. Data acquisition from S/5 GE Datex anesthesia monitor
655 using VSCapture: An open source.NET/Mono tool. *J. Anaesthesiol. Clin. Pharmacol.* **29**,
656 423–424 (2013).
- 657 87. Zhang, J., Cavanaugh, D. J., Nemenov, M. I. & Basbaum, A. I. The modality-specific
658 contribution of peptidergic and non-peptidergic nociceptors is manifest at the level of
659 dorsal horn nociresponsive neurons. *J Physiol (Lond)* **591**, 1097–1110 (2013).
- 660 88. Wasilczuk, A. Z., Meng, Q. C. & McKinstry-Wu, A. R. Electroencephalographic evidence
661 for individual neural inertia in mice that decreases with time. *Front. Syst. Neurosci.* **15**,
662 787612 (2021).

- 663 89. Jarvie, B. C., Chen, J. Y., King, H. O. & Palmiter, R. D. Satb2 neurons in the
664 parabrachial nucleus mediate taste perception. *Nat. Commun.* **12**, 224 (2021).
- 665 90. Mukamel, E. A., Nimmerjahn, A. & Schnitzer, M. J. Automated analysis of cellular signals
666 from large-scale calcium imaging data. *Neuron* **63**, 747–760 (2009).
- 667






Fig. 2. Nitrous oxide preferentially activates excitatory ACC neurons. (A) Left: Simplified circuit illustrating the local connectivity of molecularly distinct cortical neurons. Right: Spontaneous activity of molecularly distinct ACC neurons monitored during inhalation of nitrous oxide, after their restricted labeling with GCaMP6f using a combinatorial viral/genetic approach. (B) Selective labeling of molecularly distinct populations. (C) Heatmap of changes in event rate induced by nitrous oxide or control gas (oxygen); z-score normalized to baseline activity prior to gas exposure (white line). (D) Changes in neural activity (z-scored event rate) across different neural subtypes as a function of nitrous oxide concentration (colored line: mean, gray area: SEM). (E) Representation of neural activity patterns using t-distributed stochastic neighbor embedding (tSNE), colored by neural activity. (F) Mean normalized event rate of identified clusters (top; line: mean, gray area: standard deviation) and the preferential recruitment of distinct molecular subtypes to individual clusters by gas exposure, displayed as median and interquartile range (two-way repeated measures ANOVA, FDR corrected).




Fig. 3. Nitrous oxide predominantly activates excitatory ACC neurons in cortical layer 2/3. (A,B) Fos immunofluorescence, a correlate of neuronal activity, after exposure to air or nitrous oxide (60%). (C) Quantification of ACC Fos labeling (Student's t-test, $p < 0.039$). (D) Cortical layer-specific changes in Fos labeling (two-way ANOVA, FDR corrected). (E) Immunofluorescence labeling of Fos-expressing neurons (red) and inhibitory neurons with GFP in GAD67-GFP mice (green). White arrows indicate double-labeled cells. (F) Quantification of Fos-expressing ACC inhibitory interneurons (student's t-test, $p < 0.008$). White scale bars in (B) and (E) equal 50 microns.




Fig. 4. Nitrous oxide-induced reduction of affective-motivational pain-related behaviors correlates with changes in noxious stimulus-evoked ACC activity. (A) Behavioral responses to noxious heat (high-power infrared laser) monitored during inhalation of control gas (air) or nitrous oxide (60%). (B) Heat-evoked reflexive and affective-motivational behaviors. (C) Reflexive and affective-motivational behavioral responses to noxious stimuli during inhalation of nitrous oxide, quantified as percent of trials (paired t-test, reflexes: $p < 0.0082$; licks: $p < 0.0001$). (D) Percentage of licks that occur with reflexive behaviors (paired t-test, $p < 0.0001$). (E) Noxious stimulus-evoked ACC activity monitored in awake, freely behaving mice during inhalation of nitrous oxide. GCaMP6f virally-expressed in excitatory neurons (CaMK2 α). (F) Heatmap of changes per neuron (rows) in calcium dynamics (z-scored and averaged across trials) provoked by laser stimulus (white line) during nitrous oxide or air. (G and H) Noxious stimulus-evoked neural activity during inhalation of nitrous oxide or air displayed as absolute event rate (G, events/second) and baseline normalized event rate (H) ($n = 9$ mice). (I) Left: Quantification of baseline and laser-evoked neural activity illustrated in G and H (paired t-test). Right: Simple linear regression of normalized maximum event rate versus licks ($R^2 = 0.382$, $p < 0.006$) or reflexes ($R^2 = 0.017$, $p < 0.610$). (J) Left: Neurons with significantly altered calcium dynamics following laser stimulation as a percentage of the total number of neurons identified per mouse, quantified from (F) (paired t-test). Right: Simple linear regression of the percentage of neurons with altered activity versus licks ($R^2 = 0.235$, $p < 0.042$) or reflexes ($R^2 = 0.046$, $p < 0.390$). Data for plots in C, D and J displayed as median and interquartile range; bar graphs in I displayed as mean \pm SEM; regressions in I and J displayed as best fit line and 95% confidence interval. $N = 30$ mice for panels C and D. $N = 9$ mice for panels F through J.




Fig. 5. Neural signatures of pain during general anesthesia. (A) Noxious (laser) stimulus-evoked ACC activity monitored in awake, freely behaving mice inhaling air and in anesthetized mice inhaling isoflurane (1%). GCaMP6f virally-expressed in excitatory neurons (CaMK2 α). (B) Behavioral and imaging endpoints: left: loss of righting reflex/absence of volitional movements; middle: presence of nociceptive reflexes; right: percent of spontaneously active neurons (isoflurane compared to air). Data displayed as median and interquartile range. (C) Heatmap of calcium dynamics (z-scored and averaged across trials) per neuron in response to laser stimulus (white line) during isoflurane or air. (E and F) Laser-evoked neural activity during inhalation of isoflurane or air displayed as absolute event rate (E, events/second) and baseline normalized event rate (F). (G) Baseline and laser-evoked neural activity quantified from E (baseline and max event rate), F (fold change in max event rate), and C (percent of neurons with evoked activity) (paired t-test). (H) Noxious stimulus-evoked affective-motivational behaviors (licks) observed in awake mice (solid bar) and those predicted by noxious stimulus-evoked ACC activity (striped bars). N = 5 mice per group for all panels.